In brief
- Four US lawmakers—three Republicans and one Democrat—have introduced the “IBOGAINE Act” to codify parts of the White House’s executive order on psychedelics into law.
- The introduced text proposed steps within sixty days of possible enactment to determine whether to move ibogaine from Schedule I (no recognized medical use) to Schedule II of the Controlled Substances Act.
- The introduced version was not a clinical-access authorization; this review does not certify later proceedings or laws.
A bipartisan group introduced H.R.9559, the IBOGAINE Act, on June 30, 2026. Its sponsors link it to the executive order on psychedelics from the White House. This review checked the introduced version, not current legislative status or an enacted law.
Who is behind it and what it proposes
The introduced version identifies Morgan Luttrell as sponsor, with Michael McCaul, Jack Bergman and Lou Correa. Its full title is Initiating Biomedical Outcomes to Garner Advancements into Innovative Neuroplastogen Efficacy Act. Neuroplastogen is language used in the bill and sponsors’ debate, rather than a clinical certification of efficacy or safety.
What would change in practice
Section 10(b) of the introduced text would direct the Attorney General to take necessary steps to determine whether ibogaine and its compounds move from Schedule I to II within sixty days of possible enactment. It does not order automatic transfer. Section 10(a) proposes proceedings to determine another schedule for Schedule I drugs successfully completing phase 3 for serious mental disorders, not a universal rule for every substance. Other sections propose priority-review vouchers, Right to Try changes and special registrations, plus HHS–VA collaboration with the private sector. These are provisions in a proposal, not verified services or current rights established by this review.
What it implies
Introducing a bill is not enacting it or authorizing treatment. The GovInfo version reviewed documents introduction and committee referral on June 30; Congress.gov could not be opened to check current progress. The earlier assertion of no later votes is not retained as a current fact. Nor does this review certify it as the first such initiative or predict implementation: deadlines conditional on possible enactment are not present access dates.
Source
- Marijuana Moment. Bipartisan Congressional Bill Would Codify Trump’s Psychedelics Order Into Law. Marijuana Moment, July 1, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
